3 pharma stocks you should consider selling

Recently, it has become apparent that some pharmaceutical company stocks pose a significantly elevated risk. Increased regulatory scrutiny and growing competition from the sector is putting some firms under considerable pressure. Economic and market factors such as changes in patent protection and price wars further complicate the situation.

Read on to find out why you should consider selling shares in three specific companies that are in difficult situations and whose future prospects are not promising.

Moderna $MRNA

Moderna, a U.S. biotechnology company that has become a major player due to its rapid development of a vaccine against COVID-19, is now facing the challenges of declining sales. In 2023, the company saw a significant drop in revenue to $6.8 billion compared to $19.3 billion in 2022. This decline was largely due to a reduction in demand for their COVID-19 vaccines, leading to major changes in the company's financial health. Profits that were positive in 2022 turned into a net…